The fact that IGF-I partially restore cognitive impairment observed in neurodegenerative diseases such as diabetes (present results) or Alzheimer’s disease (Zegarra-Valdivia et al., 2019), and in aging (Garcia-Magro et al., 2022) suggest that the reduction of IGF-I signaling may be involved in these processes. This evidence concerns the gene IGF1 and Alzheimer disease.